New hope for advanced stomach and pancreatic cancers: extra attack when DNA levels hit zero

This study tests whether adding a second round of targeted treatment (called cytoreductive intervention) after standard chemotherapy can help people with advanced upper GI cancers live longer without the disease getting worse. It is for patients whose cancer has spread but whose tumor DNA in the blood becomes undetectable after initial chemo. About 54 participants will be randomly assigned to either continue standard care or receive the extra treatment. The goal is to see if the extra step delays cancer progression and improves survival.